InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,762.48
(
0.42%
)
US TECH 100
19,481.60
(
0.06%
)
Dow Jones
42,330.15
(
0.04%
)
Brent Oil
71.76
(
-0.32%
)
Bitcoin
63,313.70
(
-0.03%
)
Post# of 4273
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

iDeVos

Send PM Follow Ignore
Followers 1
Posts 23
Boards Moderated 0
Alias Born 02/07/2019

iDeVos

Re: None

Friday, 03/01/2019 2:16:56 PM

Friday, March 01, 2019 2:16:56 PM

Post# of 4273
Not sure if I'm missing anything but looking at the financial statements (click this link to view), but after completing the transaction with BHC, Synergy will be able to pay off the debts and still retain the core GI platform (uroguanylin) along with a total cash/assets valued near $100M.
Since they're no longer running any clinical trials, their operating expenses and other legal costs (cash burn) in the last 4 months would probably be around $30M -> $40M, and they still have over $60M in total cash/asset value.

With SGYP is currently traded @ ~ $0.07/share (under $20M marketcap), I think it's a buying opportunity (?)
https://www.sec.gov/ix?doc=/Archives/edgar/data/1347613/000134761318000032/sgyp-20180930.htm
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up